Heparin chromatography as an
FcRn
Pharmacokinetics
clearance
heparin
neonatal Fc receptor
pinocytosis
prediction
Journal
mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829
Informations de publication
Date de publication:
Historique:
entrez:
27
11
2019
pubmed:
27
11
2019
medline:
9
1
2021
Statut:
ppublish
Résumé
The pharmacokinetic (PK) properties of therapeutic antibodies directly affect efficacy, dose and dose intervals, application route and tissue penetration. In indications where health-care providers and patients can choose between several efficacious and safe therapeutic options, convenience (determined by dosing interval or route of application), which is mainly driven by PK properties, can affect drug selection. Therapeutic antibodies can have greatly different PK even if they have identical Fc domains and show no target-mediated drug disposition. Biophysical properties like surface charge or hydrophobicity, and binding to surrogates for high abundant off-targets (e.g., baculovirus particles, Chinese hamster ovary cell membrane proteins) were proposed to be responsible for these differences. Here, we used heparin chromatography to separate a polyclonal mix of endogenous human IgGs (IVIG) into fractions that differ in their PK properties. Heparin was chosen as a surrogate for highly negatively charged glycocalyx components on endothelial cells, which are among the main contributors to nonspecific clearance. By directly correlating heparin retention time with clearance, we identified heparin chromatography as a tool to assess differences in unspecific cell-surface interaction and the likelihood for increased pinocytotic uptake and degradation. Building on these results, we combined predictors for FcRn-mediated recycling and cell-surface interaction. The combination of heparin and FcRn chromatography allow identification of antibodies with abnormal PK by mimicking the major root causes for fast, non-target-mediated, clearance of therapeutic, Fc-containing proteins.
Identifiants
pubmed: 31769731
doi: 10.1080/19420862.2019.1683432
pmc: PMC6927760
doi:
Substances chimiques
Histocompatibility Antigens Class I
0
Immunoglobulins, Intravenous
0
Receptors, Fc
0
Heparin
9005-49-6
Fc receptor, neonatal
TW3XAW0RCY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1683432Références
MAbs. 2015;7(5):912-21
pubmed: 26018774
J Biol Chem. 2015 Feb 13;290(7):4282-90
pubmed: 25538249
Proc Natl Acad Sci U S A. 2015 May 12;112(19):5997-6002
pubmed: 25918417
Drug Discov Today. 2006 Jan;11(1-2):81-8
pubmed: 16478695
J Mol Biol. 2007 May 4;368(3):652-65
pubmed: 17362988
MAbs. 2018 Jul;10(5):803-813
pubmed: 29621428
J Biol Chem. 2010 Feb 12;285(7):4826-36
pubmed: 20018855
MAbs. 2016 Jul;8(5):969-82
pubmed: 27111637
MAbs. 2015;7(6):1084-93
pubmed: 26337808
Mol Immunol. 2013 Dec;56(4):660-74
pubmed: 23917469
PLoS One. 2013;8(2):e57479
pubmed: 23468998
AAPS J. 2012 Sep;14(3):554-8
pubmed: 22610647
MAbs. 2018 Nov-Dec;10(8):1322-1331
pubmed: 30130450
J Immunol Methods. 2012 Jan 31;375(1-2):20-9
pubmed: 21939661
MAbs. 2016 Oct;8(7):1269-1275
pubmed: 27610650
MAbs. 2016 Aug-Sep;8(6):1064-78
pubmed: 27232760
Mol Cell Proteomics. 2017 Mar;16(3):451-456
pubmed: 28062799
Annu Rev Biochem. 1999;68:729-77
pubmed: 10872465
Int J Pharm. 2013 Jan 2;440(1):83-98
pubmed: 22227342
Protein Eng Des Sel. 2013 Oct;26(10):663-70
pubmed: 24046438
Protein Eng Des Sel. 2010 May;23(5):385-92
pubmed: 20159773
Clin Transl Sci. 2019 Mar;12(2):130-139
pubmed: 30414357
MAbs. 2014 Jul-Aug;6(4):928-42
pubmed: 24802048
MAbs. 2014;6(5):1255-64
pubmed: 25517310
J Immunol. 2006 Jan 1;176(1):346-56
pubmed: 16365427
J Immunol Methods. 2018 Nov;462:101-105
pubmed: 30030147
MAbs. 2012 Nov-Dec;4(6):753-60
pubmed: 23778268
Mol Immunol. 2006 Mar;43(9):1462-73
pubmed: 16139891
J Pharmacokinet Pharmacodyn. 2016 Aug;43(4):427-46
pubmed: 27377311
MAbs. 2015;7(3):483-93
pubmed: 25695748
BioDrugs. 2014 Apr;28(2):171-80
pubmed: 24150980
Int Immunol. 2001 Dec;13(12):1551-9
pubmed: 11717196
Int Immunol. 2006 Dec;18(12):1759-69
pubmed: 17077181
PLoS Biol. 2016 Aug 19;14(8):e1002533
pubmed: 27541692
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):944-949
pubmed: 28096333
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18601-6
pubmed: 25512516
MAbs. 2015;7(2):331-43
pubmed: 25658443
Clin Pharmacokinet. 2013 Feb;52(2):83-124
pubmed: 23299465
J Pharm Sci. 2004 Nov;93(11):2645-68
pubmed: 15389672
MAbs. 2013 Jul-Aug;5(4):576-86
pubmed: 23765230